<DOC>
	<DOCNO>NCT00054015</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness 3-AP treating patient advanced prostate cancer previously treat hormone therapy .</brief_summary>
	<brief_title>3-AP Treating Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient advance hormone-refractory prostate cancer treat 3-AP . - Determine toxic effect drug patient . OUTLINE : This multicenter study . Patients receive 3-AP IV 2 hour day 1-4 . Treatment repeat every 2 week 1 year absence disease progression unacceptable toxicity . Patients follow every 2-3 month 1 year . PROJECTED ACCRUAL : Approximately 13-27 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hormonerefractory metastatic prostate cancer one follow method : Measurable disease PSA level least 5 ng/mL positive bone scan Objective evidence progressive metastatic disease past 3 month define follow : An increase PSA value least 25 % ( minimum absolute increase 5 ng/mL ) least 2 successive occasion , least 2 week apart A new symptomatic lesion bone scan A new metastasis bone Growth exist nonbone measurable metastatic disease NOTE : An increase pain symptom alone without evidence progression , elevation PSA serum alkaline phosphatase alone without evidence metastatic disease sufficient Prior bilateral orchiectomy primary hormonal treatment evidence treatment failure Patients prior bilateral orchiectomy must testosterone level less 50 ng/mL must continue leuteinizing hormonereleasing hormone therapy study No known active CNS metastasis ( exclude prior CNS metastasis currently stable disease treatment ) PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy More 3 month Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL ( transfusion allow ) Hepatic Bilirubin great 2.0 mg/dL ALT/AST great 5 time upper limit normal Albumin great 2.5 g/dL Chronic hepatitis allow Renal Creatinine great 2.0 mg/dL Cardiovascular No myocardial infarction within past 3 month No unstable angina No uncontrolled arrhythmias No uncontrolled congestive heart failure Pulmonary No dyspnea rest Other Nutrition adequate ( caloric intake consider adequate maintenance weight ) Fertile patient must use effective contraception No prior concurrent malignancy except nonmetastatic basal cell squamous cell skin cancer stage I malignancy curatively resect 5 year ago No active uncontrolled infectious process No lifethreatening illness No peripheral neuropathy great grade 2 PRIOR CONCURRENT THERAPY : Biologic therapy At least 2 week since prior biologic therapy Chemotherapy At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No 1 prior chemotherapy regimen metastatic disease Endocrine therapy See Disease Characteristics At least 4 week since prior hormonal therapy include follow : Megestrol Finasteride Herbal product know decrease PSA level ( e.g. , saw palmetto PCSPES ) Systemic corticosteroid At least 4 week since prior flutamide therapy ( 6 week bicalutamide nilutamide ) continue evidence progressive disease document least 1 PSA value discontinuation Radiotherapy At least 8 week since prior radiopharmaceutical ( strontium chloride Sr 89 , samarium Sm 153 lexidronam pentasodium ) At least 4 week since prior radiotherapy recover Surgery See Disease Characteristics At least 3 week since prior major surgery recover Other No concurrent investigational agent No concurrent anticancer treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>